BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.

[1]  C. Flohr,et al.  Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  T. Agner,et al.  Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry , 2022, Acta dermato-venereologica.

[3]  T. Bieber,et al.  Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  S. Feldman,et al.  The evolving atopic dermatitis management landscape , 2022 .

[5]  A. Salman,et al.  Real‐life effectiveness and safety of dupilumab in adult patients with moderate‐to‐severe atopic dermatitis , 2021, Dermatologic therapy.

[6]  E. Haufe,et al.  Status report on the atopic dermatitis registry TREATgermany , 2021, Allergologie select.

[7]  M. Llamas-Velasco,et al.  Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry , 2020 .

[8]  L. Naldi,et al.  TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema , 2019, The British journal of dermatology.

[9]  H. Williams,et al.  Strengths and limitations of the United Kingdom Working Party criteria for atopic dermatitis in adults , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  I. Zalaudek,et al.  Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis , 2019, The Journal of dermatological treatment.

[11]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[12]  F. Vanaclocha,et al.  Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. , 2017, The Journal of investigative dermatology.

[13]  F. Vanaclocha,et al.  Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. , 2012, Archives of dermatology.

[14]  R. Hay,et al.  The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation , 1994, The British journal of dermatology.

[15]  F. Vanaclocha,et al.  BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report , 2011 .